Novartis Ag

Portola Pharmaceuticals, Inc.

Jagotec Ag

Julien Taillemite

Pascal Grenier

Ulrich Meier

Alain Nhamias

Nicole Bieri

Adrian Schmidt

Dieter Becker

Klaus-Peter Moll

Marie-Pierre Filliot

Hans De Waard

Tanja Meister

Markus Krumme

Severine Serreau

A method for preparing granules. A slurry containing solid API powder particles dispersed in a liquid is prepared. The slurry is fed to a granulator and mixed with a dry base powder within the granulator in order to produce a slurry/base powder mixture. The slurry/base powder mixture produced within the granulator is dried in order to obtain granules containing the solid API particles and the base powder.

Method for preparing granules

The present invention relates to a novel crystalline anhydrous form of [(5-chlorothiophene-2-ylsulfonylcarbamoyl)-(4-(6-fluoro-7-(methylamino)-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)phenyl)amide, potassium salt, and its use in the treatment or prevention of a condition or a disorder with platelet ADP receptor inhibition, in particular, P2Yinhibition, in animals, particularly humans. It also relates processes for making such a novel crystalline form. The present invention also relates to a solid, oral formulation of this novel crystalline form, its preparation and use thereof. 

Pharmaceutical compositions, dosage forms and new forms of the compound of formula (I), and methods of use thereof

A dosage form exhibiting delayed transit time through the GI tract. The dosage form comprises a plurality of buoyant particles, each comprising an inner drug-containing core, an intermediate layer surrounding said core and a release rate-controlling outer coating.

Pharmaceutical composition containing coated, floating particles

Growing community of inventors

Huningue, France

Julien Taillemite